Colorectal cancer tumor phenotypes associated with KRAS, NRAS, and BRAF hot-spot mutations

Table 1 Baseline characteristics of the study cohort (n = 799)

Characteristics	Number of patients	Percentage
Age at diagnosis
mean ± SD	61.8 ± 12.8	N/A
Median, IQR	62-16.5	N/A
Sex
Male	533	66.7
Female	266	33.3
Race/ethnicity
White	439	54.9
Black	167	20.9
Hispanic	175	21.9
Other	18	2.3
NM_004985.5 (KRAS) mutations
Wildtype	483	60.5
c.35G>A (p.Gly12Asp)	108	13.4
c.35G>T (p.Gly12Val)	72	9.0
c.34G>T (p.Gly12Cys)	25	3.1
Other p.Gly12 mutations	31	3.9
c.38G>A (p.Gly13Asp)	62	7.8
p.Gln61 mutations	18	2.3
NM_002524.5 (NRAS) mutations
Wildtype	738	92.3
p.Gln61 mutations	21	2.7
Other mutations	13	1.7
Unknown	27	3.3
NM_004333.6 (BRAF) mutations
Wildtype	746	93.4
c.1799T>A (p.Val600Glu)	48	6.0
Unknown	5	0.6
DNA MMR
MMR-proficient	709	88.6
MMR-deficient	84	10.5
Unknown	6	0.9
Primary tumor site
Right colon	244	30.5
Transverse colon	51	6.4
Left colon	281	35.2
Rectum	223	27.9
Familial risk
No	455	56.9
Yes	344	43.1
Tobacco use
No	296	37.0
Yes	503	63.0
Number of comorbidities
0	146	18.3
1 or 2	357	44.7
3 or more	296	37.0

BRAF: V-raf murine sarcoma viral oncogene homolog B1; KRAS: Kirsten rat sarcoma viral oncogene homolog; NRAS: Neuroblastoma RAS viral oncogene homolog; CI: Confidence interval; OR: Odds ratio; MMR: Mismatch repair; IQR: Interquartile range; N/A: Not applicable.